Senseonics (NYSE:SENS) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Senseonics (NYSE:SENS) issued its quarterly earnings results on Monday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.09), RTT News reports. Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. During the same period in the prior year, the company earned ($0.07) EPS. Senseonics updated its FY 2025 guidance to EPS.

Senseonics Stock Up 2.4 %

SENS stock opened at $0.87 on Tuesday. The business’s 50-day moving average price is $0.85 and its 200-day moving average price is $0.53. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. Senseonics has a twelve month low of $0.25 and a twelve month high of $1.40. The stock has a market cap of $517.93 million, a P/E ratio of -6.69 and a beta of 0.69.

Insider Buying and Selling

In other news, CEO Timothy T. Goodnow acquired 315,000 shares of Senseonics stock in a transaction on Tuesday, December 10th. The shares were acquired at an average price of $0.31 per share, with a total value of $97,650.00. Following the purchase, the chief executive officer now directly owns 11,310,355 shares in the company, valued at $3,506,210.05. The trade was a 2.86 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Frederick T. Sullivan acquired 124,933 shares of Senseonics stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the purchase, the chief financial officer now owns 2,478,844 shares in the company, valued at approximately $941,960.72. The trade was a 5.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

SENS has been the subject of several research analyst reports. StockNews.com initiated coverage on Senseonics in a report on Thursday, December 26th. They issued a “sell” rating for the company. HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.